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Abstract
Cancer cells subvert host immune surveillance by altering immune checkpoint (IC) proteins. Some Epstein−Barr virus
(EBV)-associated tumors have higher Programmed Cell Death Ligand, PD-L1 expression. However, it is not known how
EBV alters ICs in the context of its preferred host, the B lymphocyte and in derived lymphomas. Here, we found that latency
III-expressing Burkitt lymphoma (BL), diffuse large B-cell lymphomas (DLBCL) or their EBNA2-transfected derivatives
express high PD-L1. In a DLBCL model, EBNA2 but not LMP1 is sufficient to induce PD-L1. Latency III-expressing
DLBCL biopsies showed high levels of PD-L1. The PD-L1 targeting oncosuppressor microRNA miR-34a was
downregulated in EBNA2-transfected lymphoma cells. We identified early B-cell factor 1 (EBF1) as a repressor of miR-
34a transcription. Short hairpin RNA (shRNA)-mediated knockdown of EBF1 was sufficient to induce miR-34a
transcription, which in turn reduced PD-L1. MiR-34a reconstitution in EBNA2-transfected DLBCL reduced PD-L1
expression and increased its immunogenicity in mixed lymphocyte reactions (MLR) and in three-dimensional biomimetic
microfluidic chips. Given the importance of PD-L1 inhibition in immunotherapy and miR-34a dysregulation in cancers, our
findings may have important implications for combinatorial immunotherapy, which include IC inhibiting antibodies and
miR-34a, for EBV-associated cancers.
Introduction
Among non-Hodgkin lymphoma (NHL), more than 95% of
endemic BLs are associated with Epstein−Barr virus
(EBV). Diffuse large B-cell lymphomas (DLBCLs) con-
stitute about 30% of all NHLs, of which about 10% are
EBV associated in immunocompetent patients [1]. Its high
frequency makes DLBCL one of the most common cancers
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in adults [2]. It is noteworthy that the annual global number
of cases of EBV-positive DLBCLs supersede the total
number of BLs. Additionally, EBV is the cause of lym-
phomas arising in immunocompromised individuals such as
AIDS and transplant patients [3]. This clearly suggests that
EBV’s ability to cause cancer lies in its capacity to evade
host immune surveillance.
EBV generally establishes one of the following four forms
of latency, depending upon the phenotype and the transcrip-
tion factor repertoire of the infected cells [4]. A complete lack
of any virally encoded latent gene expression program as that
seen in the resting memory B cell is called latency 0. The
expression of the virally encoded EBNA1 and EBERs
represents type I latency. EBV-infected normal B lympho-
cytes express type I latency in vivo [5]. Under pathological
conditions, the viral latent-gene expression varies in different
tumors. The phenotypically representative BL and corre-
sponding cell lines express EBNA1 and LMP2A. When these
lines drift towards an immunoblastic phenotype, the viral
gene expression is expanded to all growth transformation
proteins, EBNA1 to -6 and LMP1, -2A, and -2B. Collec-
tively, this is known as the type III program. The viral latent-
gene expression observed in NPC and Hodgkin lymphoma is
of intermediate type II latency (LMP1+EBNA2−) [6].
The ability of EBV to transform normal B lymphocytes
into permanently growing lymphoblastoid cell lines (LCLs)
is attributed to its latent proteins. Among these, LMP1 and
EBNA2 have been extensively studied [7, 8]. In particular,
it is known that EBNA2 is sine qua non for the virus to
transform B cells [9]. Indeed, in keeping with its importance
in transformation, EBNA2 expression ensues early after
EBV infects naive B cells [10]. This viral protein is also a
potent activator of transcription such as CD23 and C-myc
[11, 12] but can also negatively regulate genes like BCL6
and Ig [13, 14]. It is a functional homolog of intracellular
(Ic) Notch, although they are not interchangeable [15, 16]. It
does not bind directly to DNA but activates transcription of
many target genes by binding to the transcription factor,
RBP-Jk [17]. EBNA2 colocalizes with another B-cell-
specific DNA binding transcription factor, EBF1 [16],
which is essential for the commitment and maintenance of
B-cell transcription program [18, 19].
Immune checkpoints (IC) regulate T-cell responses to
maintain self-tolerance. They deliver costimulatory and
coinhibitory signals to T cells [20]. PD-L1, mainly
expressed by antigen-presenting cells engages its receptor
PD-1 on T cells, to provide a growth inhibitory signal.
Different tumors express high PD-L1 to evade immune
recognition and consistently, inhibition of PD-1/PD-L1 and
other IC molecules have become important targets of cancer
immunotherapy [21].
MicroRNAs (miRNAs) are small noncoding RNAs that
post-transcriptionally regulate gene expression [22, 23]. The
miR-34 family members are transcriptionally induced by
p53 [24]. They suppress transcription of genes important in
cell cycle progression, antiapoptotic functions, and regula-
tion of cell growth. Expression of miRNAs is altered in a
broad range of cancers, with frequent downregulation of
both p53 and miR-34 [25, 26]. The latter is downregulated
in chronic lymphocytic leukemia and acute myeloid leu-
kemia (AML) [27, 28]. Interestingly, the IC protein, PD-L1,
has been shown to be a validated target of miR-34a [29].
Based on gene expression, DLBCLs are divided into two
broad categories, the germinal center (GC) type and the
activated B-cell type (ABC) or the non-GC type [30]. The
overall survival rates in the non-GC (ABC) DLBCL
patients are poor [31–34]. EBV is associated more fre-
quently with the non-GC DLBCLs [2], which generally
express high levels of PD-L1 [31]. Both EBV associated
and high PD-L1 expressing non-GC DLBCLs have a very
poor prognosis [31, 35]. In other hematological malig-
nancies, like Hodgkin Lymphoma (HL), high PD-L1
expression has been reported due to either selective
amplification of the PD-L1 locus on chromosome 9p24.1 or
EBV infection [36]. These two modes of PD-L1 upregula-
tion are mutually exclusive [37]. It was also shown that
LMP1 expression induced PD-L1 promoter activity in B
cells [37]. In addition, more than 70% of post-transplant
lymphoproliferative disorders, of which EBV is the cause,
express PD-L1 [37]. In DLBCL, Kwon et al. [32] observed
that PD-L1 expression was positively correlated with
EBV’s presence in ABC type DLBCL.
Although the presence of EBV is correlated with higher
expression of PD-L1 both in HL and DLBCLs, it is not
clear if and how the virus is responsible for an increased
PD-L1 expression and if this applies to other lymphomas
like BLs, as well. While LMP1 has been implicated in
induction of PD-L1 in HEK293 cells [37] or in epithelial
cells [38], it is not known if other EBV encoded genes like
EBNA2 can regulate PD-L1 in a more frequent cellular
setting and natural reservoir for EBV, such as B cells. In
this study, we set out to investigate if EBNA2, which is
indispensable for EBV’s ability to transform B cells, has
any effect on PD-L1 and if this involves regulation of cel-
lular miRNAs.
Methods
Cells
Mutu I and Mutu III, Daudi, Jijoye are EBV-positive BLs.
LCL is an EBV-positive cell line. OMA4 [39], DG75, and
BL41 are EBV-negative BLs. U2932, SUDHL5 are EBV-
negative GC-type DLBCLs. ER/EB 2.5 is an estradiol-
inducible EBNA2 carrying cell line [40]. The details of the
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cell lines infected with recombinant EBV [14, 41–43] and
EBNA2/ LMP1 transfectants [14, 44] have been described
previously.
Infection with a recombinant EBV strain
The recombinant strain of Akata EBV [45] was a kind gift
from Prof. Kenzo Takada (Hokkaido University, Sapporo,
Japan). The induction of lytic replication, virus production
by engaging IgG with corresponding antibodies and infec-
tion procedure has been described in detail by us previously
[14, 41, 42]. The supernatant containing recombinant EBV
was used to infect EBV-negative U2932, SUDHL5, OMA4,
and DG75 cells.
EBNA2 and LMP1 transfection and selection
An EBNA2 expression vector J144-C1, the expression
vector for LMP1 J132-G5 and the corresponding vector
control pSV-MPA GPT (a kind gift from Prof. Lars Rymo,
Gothenburg University, Sweden) were individually trans-
fected into U2932 DLBCL cells by electroporation. The
transfection and selection details have been described by us
previously [14, 46]. BL41K3 cells transfected with
estrogen-inducible EBNA2 were treated with 1 µM estradiol
to induce EBNA2 expression [44].
Immunoblotting
EBNA2 and LMP1 expression was verified by monoclonal
antibodies PE2 (Kindly provided by Dr. Martin Rowe,
Birmingham University Medical School) [47] and S12
monoclonal antibodies (a kind gift from the late
Dr. David Thorley-Lawson, Tufts University, Boston,
USA), respectively. β-actin antibodies were purchased
from Sigma. PD-L1 (E1L3N, cat# 13684) and p21 (#2947)
and BCL2 (#15071) were purchased from Cell Signaling.
Further details of the method are in supplementary
information.
Quantitative RT-PCR (qRT-PCR)
Total RNA from cell lines was isolated using Direct-zol
RNA MiniPrep Plus kit (Zymo Research) according to the
vending company’s instructions. The integrity of RNA was
routinely checked using 1% agarose gel and RNA quanti-
fication was estimated with a DS-11 spectrophotometer
(DeNovix) [48]. The cDNA synthesis for mature miR-34a
was performed according to the manufacturer’s instructions
(miScript II RT Kit, Qiagen). For verification of pre-miR-
34a expression, reverse transcription qPCR was performed.
Further details of the method can be found as supplemen-
tary information.
Knockdown of miR-34a and miR-34 mimic
transfection
The U2932 vector control or EBNA2-expressing clones
were transfected with 50 nM of miR-34a inhibitors (mir-
Vana), mimic miR-34a oligonucleotides or mimic controls,
purchased from Ambion. The compounds were delivered
into the cells with DharmaFect Duo transfection reagent
(GE Dharmacon). After 48 h, the cells were harvested for
total RNA and protein extraction.
miR-34a promoter and biosensor luciferase
reporters
To investigate the effect of EBNA2 on miR-34a promoter,
50,000 EBNA2-expressing U2932 and BL41 cells were
seeded in triplicates in a 96-well plate. The cells were co-
transfected with 1 µg/µl of pRL-TK luciferase control
reporter (Promega) and 0.5 µg/µl miR-34aP luciferase
reporter, which carries the wild-type miR-34a promoter
(Addgene plasmid # 50827). After 48 h, the cells were
harvested and lysed in 80 µl passive lysis buffer (Promega).
Firefly and Renilla luciferase activity was detected by
GloMax explorer luminometer (Promega). To verify miR-
34a mimic transfection efficiency in U2932 and EBNA2
clone 1, 50 nM miR-34a mimics were co-transfected with
20 ng of miR-34a or miR-34a mismatch biosensors. Both
biosensors were generated by cloning the reverse miR-34a
or miR-34a mismatched complementary sequence cloned
downstream of the Renilla promoter in the psiCheck-2 dual
luciferase reporter plasmids (Promega), as previously
described [49, 50]. After 48 h post-transfection, the cells
were lysed in 80 µl passive lysis buffer (Promega). Firefly
and Renilla luciferase activity was detected by GloMax
explorer luminometer (Promega).
PD-L1 luciferase reporters and activity
PD-L1 3′UTR Luciferase reporter construct was made as
follows. The full-length PD-L1 3′UTR (2674 bp) (ref|
NM_014143.3| Homo sapiens CD274 molecule (CD274),
transcript variant 1, mRNA) was PCR amplified from human
genomic DNA (Thermo Fisher #4312660), in three separate
fragments. Fragment 1 was generated with primers F:
GAGACGTAATCCAGCATTGG and R1: CTGAGGT
CTGCTATTTACTGG; Fragment 2 was generated with
primers F1: CCAGTAAATAGCAGACCTCAG and R2:
GACTAGATTGACTCAGTGCAC; Fragment 3 was gen-
erated with primers F2: GTGCACTGAGTCAATCTAGTC
and R: TAACTTTCTCCACTGGGATG. The three frag-
ments were connected by overlap PCR, with forward
primer: actcgagGAGACGTAATCCAGCATTGG (contain-
ing a XhoI site, underlined) and reverse primer:
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agcggccgcTAACTTTCTCCACTGGGATG (containing a
NotI site, underlined). The full-length PD-L1 3′UTR was
cloned into the Psicheck2 vector between the XhoI and NotI
sites downstream of Renilla luciferase, and fully verified by
sequencing. Further details are enclosed in the supplemen-
tary information.
Site-directed mutagenesis of PD-L1 3′UTR
Point mutations were introduced into the miR-34a seed
sequence of 3′UTR of PD-L1 cloned in Psicheck-2 vector
according to the QuikChange site-directed mutagenesis kit
(Agilent Technologies). The mutagenic primers containing
the desired mutation in the miR-34a seed sequence of the 3′
UTR of PD-L1 were: Forward primer: 5′-GAAG-
CAACTGCTACGAACGTTCATTCATATG-3′ and the
reverse primer: 5′-CATATGAATGAACGTTCGTAGCA
GTTGCTTC-3′. The miR-34a seed sequence in the wild
type 3′-UTR of PD-L1 is in bold letters: 5′-GAAG-
CAACTGCTACTGCCTTTCATTCATATG-3′. TGCCT
was mutated to GAACG. The mutated seed sequence was
verified by sequencing.
EBF1 knockdown
Knockdown of EBF1 was obtained by transduction of
U2932 and its EBNA2 expressors with pLK0.1 lentiviral
vectors, which carry shEBF1 and the corresponding
control shRNA (TRC Human EBF1 shRNA, Clone
ID: TRCN0000013831 and Plko.1-emptyT control
TRCN0000208001, Open Biosystems, Dharmacon). Cells
were transduced as described below and were selected with
1.5 µg/ml puromycin for 10 days and used for further
experiments.
Lentivirus transduction
The cell lines U2932 MPA vector and U2932 EBNA2 were
transduced with pLL3.7_hsa-miR-34a (Addgene plasmid #
25791) and pLL3.7 control vector (Addgene plasmid #
11795). For the production of lentiviruses, viable and
confluent HEK293T cells were transfected (Fugene6, Pro-
mega) with the transfection mixture composed of 10 µg of
pLL3.7_hsa-miR-34a or pLL3.7 vector control along with
5 µg pMD2.G envelope plasmid (Addgene plasmid #
12259) and 5 µg psPAX2 packaging plasmid (Addgene
plasmid #12260). The method is further detailed as sup-
plementary information.
Standard mixed lymphocyte reaction (MLR)
PBMCs were isolated from the blood of healthy donors
using Ficoll-Paque separation media (GE Healthcare) and
were seeded in 24-well non-tissue culture-treated plates
(Falcon, Fisher, Pittsburgh, PA, USA), previously coated
with anti-CD3 (clone-UCHT1; Pharmingen, San Diego,
CA, USA) and anti-CD28 (clone-CD28.2; Pharmingen, San
Diego, CA, USA) at the concentration of 1 μg/ml in
phosphate-buffered saline (PBS) at 0.4 ml/well overnight
at 4 °C.
The day after, the plates were washed in 1× PBS and
PBMCs were added to the CD3/CD28-coated wells at a
density of 1×106 cells/well and cultured for 72 h, in order to
activate the CD4 and CD8 cell population.
One day before seeding the stimulators, 1×105 U2932
MPA vector and U2932 EBNA2 cl-1 were transiently
transfected with 50 nM mimic negative control and mimic
miR-34a (Ambion) and subsequently irradiated with a sub-
lethal dose of 5 Gy for 2 min. The cells were placed in
coculture with 1×106 PBMCs. At 72 h post-transfection and
after 48 h coculture, all samples were treated for 5 h with
GolgiStop™ (BD Biosciences) to block cytokine
accumulation in the Golgi complex, for the detection of
IFN-γ-producing cells, by flow cytometry. Additional
details are in supplementary materials and methods.
The entire population of co-cultured cells was stained
with FITC mouse anti-human CD8 and Pacific Blue mouse
anti-human CD4 (BD Pharmingen) for detection
of T cells. The same cells were then permeabilized with
cytofix/cytoperm buffer (BD Pharmingen), according to the
manufacturer’s instructions. The cells were stained intra-
cellularly with human IFN-γ, R-PE (Invitrogen).
A matched isotype control, anti-Human IgG Fc secondary
antibody, PE (Invitrogen), was also included in this
experiment. Sample acquisition was performed with Gallios
Flow Cytometer. The data were analyzed with Kaluza for
Gallios Software.
3D microfluidic platform for T-cell responses to
EBNA2-transfected U2932 DLBCL
The 3D microfluidic chips, polydimethylsiloxane (PDMS,
Sylgard 184, Dow-Corning, Midland, Michigan) micro-
fluidic devices were fabricated using soft lithography as
described previously [51, 52]. The devices were treated with
0.01% v/v poly-L-lysine and 0.5% v/v gluteraldehyde to
promote collagen/fibronectin adhesion. After washing
overnight in water, steel acupuncture needles (160 μm dia-
meter, Seirin, Kyoto, Japan) were introduced into the
devices and a solution of 2.5 mg/ml type 1 collagen, 1×
M199 medium, 1 mM HEPES, 0.1 M NaOH and
NaHCO3 (0.035% w/v) and 200 ng/ml Fibronectin (Thermo
Fisher Scientific, Waltham, MA) was infused into the
devices and allowed to polymerize for 40 min at 37 °C.
Subsequently, needles were removed to create 160 μm
diameter channels within collagen/fibronectin gel and cells
Epstein−Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in. . . 135
were introduced into devices. In coculture experiments,
each device was first seeded with 5×103 U2932 EBNA2 cl-
1 transduced with the control lentivirus or miR-34a con-
taining lentiviral vector and were incubated for 24 h at 37 °
C. Subsequently, 5×104 PBMCs, containing previously
activated T cells were added in complete medium (RPM1
1640/10% FBS). The devices were in triplicates and
incubated for an additional 48 h before performing
immunostaining.
For immunostaining of the cocultures in microfluidic
devices, the cells were fixed with 4% PFA for 10 min and
washed twice in PBS, permeabilized with 0.1% (v/v)
Triton X 100 in PBS for 20 min at room temperature, and
treated with a blocking solution (BSA 5% in PBS 0.1%
Triton X 100). The devices were incubated with rabbit anti-
caspase-3 (Cell Signaling) or mouse anti-CD4 and -CD8
antibodies (1:100 dilution, Biolegend) and kept on
a rocking platform O/N at 4 °C. Devices were merged in
PBS and left on a rotor O/N, at 4 °C to remove
excess antibody. The day after, PBS was removed and
Alexa 568-conjugated goat-anti-rabbit IgG (primary abs,
caspase-3) and Alexa 647-conjugated goat-anti-mouse IgG
(primary abs, CD4 and CD8) secondary antibodies diluted
1:100 in blocking buffer were added per well in each device
O/N at 4 °C. Finally, PBS was added in each device and
processed to detect caspase-3, CD4 and CD8 staining. The
devices were visualized using confocal microscope (LSM
710, Carl Zeiss), and image analysis made by ImageJ by
performing a maximum intensity z projection and merging
the channels.
PD-L1 immunohistochemistry and quantitative
analysis in biopsies from DLBCL patients
A written informed consent was obtained from all patients
involved in the study. The study design was approved by
the Institute’s ethics review board. Paraffin sections were
immunostained for PDL-1, PD-1, EBNA2, LMP1, MUM-1,
CD10, and Bcl6, using an automated immunostainer
(DAKO, Glostrup, Denmark). As control for PD-L1
immunostaining, sections from paraffin-embedded human
lung carcinoma were used. Further details are in supple-
mentary m&m. For quantitative IHC analysis, the Aperio
Imagescope algorithm was used to evaluate both percentage
positive cells and intensity of the stained tumor cells in three
regions of three clinical samples representing each of the
three types of non-GC DLBCL category (EBV neg, EBV
+/EBNA− and EBV+/EBNA2+).
Fig. 1 PD-L1 expression in EBV-infected and EBNA2-transfected BL
and DLBCL cell lines. a EBNA2 and PD-L1 expression in Mutu I
(latency I expressor) and its latency III-expressing counterpart. Fur-
thermore, expression of PD-L1 and EBNA2 is shown in two additional
BLs with resident viral genomes. Daudi carries an EBNA2-deleted
EBV strain and Jijoye is EBNA2-positive BL. b Two GC DLBCLs,
namely U2932 and SUDHL5, were infected with a recombinant Akata
strain of EBV. Total cell lysates were electrophoresed and EBNA2
expression was verified by immunoblotting using PE2 monoclonal
antibodies. PD-L1 expression was analyzed using rat monoclonal
antibodies. c Two BL cell lines, Oma4 and DG75, were infected with
the recombinant Akata virus and tested for EBNA2 and PD-L1
expression. β-actin is used as loading control. d PD-L1, EBNA2, and
LMP1 expression in transfected U2932 DLBCL and e BL41 is an
EBV-negative BL. The BL41K3 derivatives are estrogen-inducible
EBNA2 transfectants. PD-L1, EBNA2, and β-actin expression was
analyzed before and after β-estradiol treatment. β-actin is used as
loading control
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Results
PD-L1 expression is induced in latency III-expressing
BLs, in vitro infected BLs and DLBCLs and EBNA2-
transfected cells
The restricted latency expressor cell line Mutu I [53] did not
express PD-L1 while its EBNA2-expressing counterpart
showed increased PD-L1. Two additional BL cell lines,
Jijoye, which is positive for EBNA2 expression expressed
PD-L1, while EBNA2-deleted Daudi BL lacked PD-L1
expression (Fig. 1a). The above data suggest that latency
III-related viral proteins could influence PD-L1. To extend
these observations, we infected two EBV-negative GC
DLBCLs, U2932 and SUDHL5 and two EBV-negative
BLs, OMA4 and DG75 with a recombinant Akata EBV.
The resultant convertants expressed EBNA2 (Fig. 1b, c).
PD-L1 expression was strongly upregulated in both
DLBCLs (Fig. 1b) and two BLs (Fig. 1c) after in vitro EBV
infection.
From data in Fig. 1a (right panel, Daudi−Jijoye com-
parison), it became clear that EBNA2 might have a critical
Fig. 2 EBNA2 expression decreases miR-34a in transfected B lym-
phoma cells by affecting its transcription. miR-34a (top panels) and
pre-miR-34a expression (middle panels) was verified by real-time
qPCR in (a) U2932 DLBCL transfected with EBNA2 and (b) BL41K3
are transfected with estrogen-inducible EBNA2. miR-34a promoter
carrying Luc reporter activity was analyzed in U2932 and BL41 and
their EBNA2-expressing derivatives (lower panels). The figure shows
standard deviation (SD) of the average of three different experiments.
Each experiment was performed in biological triplicates for each
sample and repeated three times. p values were calculated with
unpaired t test. In all cell lines miR-34a expression (****) p < 0.0001.
Pre-miR-34a: U2932 EBNA2 cl-1 (**) p= 0.0020 and cl-2 (**) p=
0.0027, BL41K3 (****) p < 0.0001. MiR-34a promoter: U2932
EBNA2 cl-1 (***) p= 0.0002 and cl-2 (**) p= 0.0011, BL41K3
(****) p < 0.0001
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role in the observed upregulation of PD-L1. To further
confirm this, we transfected U2932 DLBCL with an
EBNA2 containing expression vector. The transfection and
selection conditions of EBNA2 and LMP1 expressing
derivatives of U2932 have been previously described in
detail elsewhere by us [54]. A strong increase in PD-L1 was
observed in EBNA2 transfectants but not in LMP1-
transfected U2932 cells (Fig. 1d, left panel). The lack of
PD-L1 induction by LMP1 was also confirmed in trans-
fected SUDHL5 DLBCL (supplementary figure 1). PD-L1
induction by EBNA2 was also confirmed by flow cytometry
as well in EBNA2-expressing U2932 (supplementary fig-
ure 2A). Additionally, in BL41 K3 cells, EBNA2 induction
by estradiol treatment was paralleled by an increase in PD-
L1 expression (Fig. 1e). PD-L1 upregulation was confirmed
by real-time q-PCR in ER/EB 2.5 cell line, which carries
estradiol-inducible EBNA2 (supplementary figure 2B).
Transcription of the PD-L1 targeting miRNA miR-34a
is downregulated by EBNA2
We have previously shown that EBNA2 can profoundly
alter cellular miRNA expression profile in U2932 cells [54].
Given the strong increase of PD-L1 expression in EBNA2-
transfected BL and DLBCLs and since miR-34a targets PD-
L1, we set out to investigate if miR-34a expression is
affected in EBNA2-expressing B lymphoma cells. As
shown in Fig. 2a, top panel, EBNA2-transfected U2932
cells showed a marked decrease in miR-34a. Similarly,
BL41K3 carrying estrogen-inducible EBNA2 showed
reduced miR-34a after estrogen treatment (Fig. 2b, top
panel). Additionally, both U2932 EBNA2 and BL41K3
cells showed reduced pre-miR-34a expression (Fig. 2,
middle panels). To further confirm that the miR-34a
decrease is transcriptional, EBNA2-expressing U2932 and
BL41 cells were transfected with miR-34a promoter carry-
ing Luc reporters. As seen in Fig. 2 (lower panels), in the
presence of EBNA2, the luciferase activity was significantly
reduced, confirming that miR-34a is indeed tran-
scriptionally affected by EBNA2.
Validation of the PD-L1 3′UTR as an miR-34a target
in U2932 DLBCL
To investigate the role of miR-34a in the regulation of PD-
L1 3′UTR, the complete 3′UTR of PD-L1 was cloned into a
luciferase reporter construct and transfected into U2932
MPA vector and U2932 EBNA2 cells. Subsequently, the
miR-34a inhibitors were introduced into the vector alone
carrying cells where miR-34a was higher. Instead, miR-34a
Fig. 3 miR-34a targets 3′UTR of PD-L1 in EBNA2-transfected U2932
cells and site-directed mutagenesis of its seed sequence abrogates its
binding to PD-L1 3′UTR. a Luciferase reporter construct containing
wild-type 3′UTR PD-L1 was transfected in presence of either miR-34a
inhibitor in MPA vector control transfectants or miR-34a mimic in
U2932 EBNA2-expressing clone. Each transfection was performed in
triplicate. For U2932 EBNA2 cl-1 is (*) p= 0.0172. b The specificity
of miR-34a binding to its seed sequence in 3′UTR of PD-L1 was
confirmed by mutating seed sequence with site-directed mutagenesis.
The mimic miR-34a bound to the wild-type 3′UTR of PD-L1 and
reduced luc activity. The inhibitory effect of mimic miR-34a was
abrogated when its seed sequence in PD-L1 3′UTR was mutated. Each
transfection was performed in triplicate. (**) p= 0.0026 refers to
U2932 MPA Vector and (**) p= 0.0021 refers to U2932 EBNA2 cl-1.
p values were calculated with unpaired t test
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mimics were transfected into EBNA2-expressing counter-
parts with low miR-34 expression. Figure 3a shows luci-
ferase activity in controls and in presence of miR-34a
inhibitor in U2932 MPA vector or miR-34a mimic in the
EBNA2 transfectant. In accordance with miR-34a down-
regulation in U2932 EBNA2, the luciferase activity was
high in these cells. When mimic miR-34a was introduced
into EBNA2-expressing cells, the reporter gene activity was
significantly reduced (Fig. 3a). To confirm the specificity of
miR-34a binding in PD-L1 3′UTR, we mutated the miR-
34a seed sequence using site-directed mutagenesis. As seen
in Fig. 3b, the wild-type 3′UTR reporter activity was high,
consistent with low miR-34a in EBNA2-expressing cl-1.
When miR-34a mimic was introduced into these cells, the
luciferase activity was reduced. In contrast, the mutated
seed sequence carrying luciferase reporters were no longer
repressed by miR-34a. This not only validated the sequence
specificity of the miRNA–mRNA binding but also mapped
and confirmed the miR-34a recognition sequence in the PD-
L1 3′UTR. The absolute expression of miR-34a in U2932
and BL41 parental cell lines and their EBNA2-expressing
counterparts in comparison with CD19+ B cells and the
Luc activity of wild-type and mutated 3′PD-L1 UTR in both
cell lines is shown in supplementary figure 3. In comparison
with normal CD19+ B cells, both U2932 and BL41 had
higher levels of miR-34a (S Figure 3A). As a consequence,
the luciferase activity of the wild-type 3′ PD-L1 UTR
construct was repressed, which indicates miR-34a binding
to the 3′UTR of PD-L1. In contrast, luciferase activity of
the mutated 3′ PD-L1 UTR was not affected by miR-34a.
Similarly, in EBNA2-transfected cells, due to lower
expression of miR-34a, the Luc activity from both WT and
mutated 3′UTR construct was not affected (S Fig. 3B).
Overexpression of miR-34a in U2932 EBNA2 cells
reduces PD-L1
Having established that miR-34a binds to 3′UTR of PD-L1,
we next investigated if miR-34a overexpression could have
a direct effect on PD-L1. For this purpose, we transfected
miR-34a mimics in U2932 EBNA2 cl-1. As seen in Sup-
plementary Figure 4, the decrease in Luc activity of the
biosensor psicheck-2 construct in the presence of miR-34a
mimic clearly suggests its successful delivery and binding
to target sequences. To investigate the direct effect of miR-
34a on PD-L1, miR-34a-transfected U2932 EBNA2 cl-1
was analyzed for PD-L1. A significant reduction in PD-L1
was observed after overexpression of miR-34a in compar-
ison to the scrambled control (Fig. 4a, b). We further
investigated if overexpression of miR-34a in U2932 cells
influences p21 and BCL2, previously shown to be
regulated by this miRNA [55]. As shown in Suppl Fig. 5A,
Fig. 4 Overexpression of miR-34a in EBNA2-expressing U2932
downregulates PD-L1. a miR-34a mimic was transfected into U2932
MPA vector and EBNA2-expressing clone 1. The transfected cells
were processed for PD-L1 expression by flow cytometry. The lower
panel indicates an average of three flow cytometry experiments and its
significance. (*) p= 0.0109. b The effect of miR-34a reconstitution on
PD-L1 expression in the vector control and EBNA2-transfected U2932
cells was also confirmed by immunoblotting. An average of the cor-
responding densitometric analysis on three such experiments is shown
in the lower panel (**) p= 0.0055. β-actin served as loading control
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U2932 EBNA2 cl-1 transfected with miR-34a had an
increased p21 but reduced BCL2. Consequently, the num-
ber of apoptotic cells was higher in miR-34a-transfected
U2932 EBNA2 cl-1 in comparison with the vector trans-
fected cells (S Fig. 5B).
EBF1 knockdown de-represses miR-34a and
downregulates PD-L1 in U2932 EBNA2 cells
Previously reported ChIP-Seq data show that EBNA2
colocalizes with EBF1 at promoter/enhancers of many
genes [16]. To identify the molecular mechanism of miR-
34a regulation by EBNA2, we analyzed EBNA2 ChIP-Seq
datasets from GEO database (accession number:
GSM2039170) and found that EBNA2 peaks at the miR-
34a promoter. Subsequently, through JASPAR database
[56] and visualization through Integrative Genomics Viewer
(IGV) [57], using the reference hg38 (human genome38),
we found multiple predicted binding sites for EBF1 at the
miR-34a promoter, and among them, one consensus
EBF1 sequence overlaps with the EBNA2 peak (Fig. 5a,
highlighted in green square). Based on this, we reasoned
that miR-34a might be regulated by EBNA2 through EBF1.
To verify this, the parental U2932 and its EBNA2-
expressing derivative line were transduced with lentiviral
vectors carrying shEBF1 and shcontrol. As shown in
Fig. 5b, upon EBF1 knockdown in U2932 EBNA2 cl1,
miR-34a and pre-miR-34a expression is derepressed with a
consequential decrease in PD-L1. We further found that
miR-34a promoter activity was increased upon EBF1 K.D.
(Fig. 5c). These data establish a circuit where EBNA2
might recruit EBF1 to miR-34a promoter to downregulate
its expression and consequently upregulate PD-L1.
Suppression of T-cell activation by EBNA2 and
increased immunogenicity after miR-34a
overexpression as measured in MLR and 3D
biomimetic microfluidic platforms
In order to understand the immunological relevance of PD-
L1 upregulation and miR-34a downregulation by EBNA2,
we first employed an MLR assay. After 3 days of PBMC
activation on CD3/CD28-coated wells, the irradiated sti-
mulator U2932 MPA vector, U2932 EBNA2 cl-1 and either
their mimic control or miR-34a-transfected derivatives were
added in an MLR. Successful miR-34a delivery in stimu-
lator cells and its binding to specific target sequence was
confirmed using the psicheck-2 biosensor reporter assay
(Suppl. Figure 6A). Effector T-cell activation was con-
firmed by a strong increase in PD-1 expression in two
donors (Suppl. Figure 6B). The activated T-cell state was
corroborated by increased IFN-γ production (Fig. 6a).
Importantly, U2932 EBNA2 cl-1 boosted IFN-γ production,
by both CD8 and CD4 T cells, only when miR-34a was
overexpressed (Fig. 6a). These data suggest that the increase
in PD-L1 by EBNA2 may have a negative effect on T-cell
activation and reconstitution of miR-34a restores immuno-
genicity of EBNA2 transfectants.
We next investigated how miR-34a might reverse the
poor immunogenicity of EBNA2-transfected high PD-L1-
expressing U2932 cells. The schematic design of the 3D
microfluidic chip-based coculture system is shown in Suppl.
Figure 7. The effector T-cell activation was confirmed by
increased IFN-γ (Suppl. Figure 8A). Stimulator U2932
EBNA2 cells tranduced either with lentiviral vectors car-
rying miR-34a or vector control were introduced into
microfluidic devices. The expression of miR-34a in
lentivirus-transduced U2932 EBNA2 cells was checked by
real-time qPCR (Suppl. Figure 8B) and the consequent PD-
L1 decrease was verified by flow cytometry (Suppl. Fig-
ure 8C). Figure 6Bi shows the device with empty lentiviral
vector-transduced U2932 EBNA2 expressors either in the
presence or absence of T cells. No significant change in
caspase-3 expression was observed. In contrast, as seen in
Figure 6bii, when miR-34a containing lentivirus was
transduced into EBNA2 U2932 clone, there was a marginal
induction of caspase-3 in the absence of T cells, most
probably due to apoptosis induced by miR-34a
expression. In contrast, overexpression of miR-34a in
EBNA2-expressing U2932, in the presence of
CD4/CD8 cells, induced significant tumor cell death, as
indicated by increased caspase-3 expression (Fig. 6bii, c).
Overall, these data suggest that reconstitution of
miR-34a in EBNA2-expressing U2932 makes them more
immunogenic.
PD-L1 and EBV correlation in clinical DLBCL samples
In a cohort of 27 cases of DLBCLs, we investigated how
EBV and EBNA2 expression is correlated with increase in
PD-L1 expression. According to the Hans Algorithm, 21
cases were classified as non-GC type and 6 cases as GC
type. Figure 7a shows PD-L1 expression in three non-GC
DLBCLs representing each category namely, EBV nega-
tive, EBV+/EBNA2−, and EBV+/EBNA2+ samples.
PDL-1 expression was detected at the cell membrane level,
in the cytoplasm or as dots in the Golgi area of the neo-
plastic cells. For quantitative estimation of PD-L1 expres-
sion and staining intensity, Aperio Imagescope analysis was
employed. The stained tissue sections were digitalized at a
×40 magnification using Aperio Scan Scope. The percen-
tage positivity was calculated by counting positive cells in
three squared areas measuring 50,000 μm2 from each clin-
ical sample. In the same areas the number of the positive
cells was determined using the Aperio software IHC
Membrane v1. The IHC Membrane Image Analysis
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algorithm detects membrane staining for individual
tumor cells in the selected regions and quantifies the
intensity and completeness of the membrane staining.
Figure 7b (upper panel) shows that there was a slight and
statistically significant overall increase in PD-L1-positive
cells in EBNA2-positive cases. Notably, as shown in
Fig. 7b, in all EBNA2+ samples analyzed, the number of
cells with high staining intensity (+2, +3) as measured by
Imagescope algorithm was significantly higher in
EBNA2+ ABC DLBCLs in comparison with EBNA2−
cases (Supp table 1).
We also analyzed PD-1 expression and found that it is
generally expressed by infiltrating cells like T lymphocytes
(TILs) and macrophages and not by the neoplastic cells.
There was no correlation between the number of PD-1-
positive infiltrating cells and PDL-1 expression by neo-
plastic cells (not shown). Suppl. Table 1 describes the
details of the clinical samples.
Discussion
Viruses, being obligate parasites, are under constant
pressure to survive in the face of strong host immune
responses. To maintain a replicative advantage, they use
multiple strategies to make themselves immunologically
invisible. This includes downregulation of HLA class I,
class II molecules, interference with peptide transport
mechanisms, inhibition of proteolysis etc. [58]. In this
regard, akin to many other viruses, EBV also employs
several mechanisms to circumvent immune eradication to
establish latency. EBV-positive DLBCLs are high PD-L1
expressors and this is confirmed here [31]. However,
which virally encoded proteins could be delegated with
this task and how do they achieve it has not been fully
explored. To the best of our knowledge, this is the first
report of how EBV, through its most critical
transformation-associated protein, EBNA2, affects PD-L1
Fig. 5 EBNA2 suppresses miR-34a transcription through EBF1. a
Prediction of EBF1 binding motifs at the miR-34a promoter in human
reference genome hg38, coordinates chr1:9181678-9182943, was
performed with the JASPAR database and visualized with IGV.
EBNA2 peak overlaps with the second of the predicted EBF1 binding
sites, highlighted in green square, on the miR-34a promoter in dataset
GSM2039170. b Knockdown of EBF1 was verified by Q-PCR in the
U2932 cell line and U2932 EBNA2 cl1 transduced with pLK0.1
lentiviral vectors which carry shEBF1 and control shRNA. Upon
EBF1 depletion (***p= 0.0004) in U2932 EBNA2 cl1, expression of
mature miR-34a (**p= 0.0023) and pre-miR-34a (**p= 0.0024) was
derepressed and consequently PD-L1 expression decreased (***p=
0.0008). Q-PCRs were performed with three biological and technical
triplicates for each sample. cMiR-34a promoter activity was enhanced
upon EBF1 knockdown in U2932 EBNA2 cl1, after 48 h. Luciferase
assay was performed three times and each sample was in triplicate.
(*p= 0.0105). Statistical analysis was performed using an unpaired t
test (Prism-7)
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expression both in DLBCLs and BLs, by downregulating
miR-34a through recruitment of EBF1 to its promoter. In
the first ever use of a microfluidic chip for EBV-associated
lymphoma growth in 3D, we further show that EBNA2-
expressing DLBCLs are less immunogenic. Reconstitution
of miR-34a in U2932 EBNA2 cells increased their
immunogenicity as seen by IFN-γ production in MLRs and
increased apoptosis as measured by caspase-3 expression
in tumor T-cell 3D cocultures.
Most EBV-positive DLBCLs are non-GC type and high
PD-L1 expressors. But it is not known if EBV directly
infects a non-GC DLBCL or whether it actually could turn a
GC DLBCL into a relatively activated DLBCL. Our data
showing strong upregulation of PD-L1 in two, in vitro
infected GC DLBCLs suggest that EBV indeed has the
ability to turn a GC-derived DLBCL into at least a partially
activated one. It is important to clarify here that U2932,
often described in the literature as ABC type, is a high
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BCL6, a hallmark of GC phenotype, expressing cell line
[14]. Furthermore, a recent detailed classification study
suggests that BCL6 is critical marker of GC DLBCL cate-
gory [59]. Additionally, most ABC DLBCLs express PD-
L1. In contrast GC DLBCLs are often PD-L1 negative.
U2932 DLBCL is indeed PD-L1 negative. Based on this,
we consider U2932 more as an intermediate phenotype
DLBCL. Patients with non-GC or activated DLBCLs have
both poor prognosis and overall survival rate [31–34].
Results from our clinical DLBCL samples suggest that
EBV-positive non-GC DLBCLs have slightly higher PD-L1
expression than those non-GC DLBCLs without the virus.
A quantitative IHC image algorithm analysis on digitalized
slides revealed that in EBNA2-positive ABC DLBCL
samples PD-L1 expression and the staining intensity was
higher. Clearly, the effect of EBNA2 alone on PD-L1 would
be impossible to determine in clinical samples because
EBNA2 alone latency does not occur in any tumor asso-
ciated with EBV. But, notwithstanding the small cohort, the
data from clinical samples confirm the in vitro data. Overall,
we suggest that the effect of EBNA2 on PD-L1 in clinical
samples will have to be tested in a larger cohort. However,
the results are consistent with the suggestion that EBNA2-
positive lymphomas may have a better therapeutic outcome
with IC blockers.
MiR-34a belongs to the group of tumor suppressor
miRNAs and accordingly, it is frequently downregulated in
a wide variety of cancers [60]. In keeping with this, its
expression is often reduced in ABC type of DLBCL cell
lines and tumor tissues [61]. Overall survival of those
patients with low miR-34a is poorer and overexpression of
miR-34a in ABC DLBCL lines makes them responsive to
doxorubicin treatment [61]. Our observations that EBNA2
downregulates miR-34a are consistent with the reported
lower expression of miR-34a in ABC DLBCLs and dox-
orubicin resistance [61]. Indeed, in Lat III ABC DLBCLs,
EBNA2 might contribute to chemoresistance and poor
prognosis by downregulating miR-34a. Additionally, Craig
et al. have shown that intravenous miR-34a treatment of
mice with U2932 DLBCL xenografts suppresses tumor
growth, thus underpinning its therapeutic utility [62].
Among its noted targets is the oncogene FOXP1 [63].
Interestingly, in AML, miR-34a targets PD-L1 [29, 64]. We
now show that EBV, through its growth transformation-
associated protein EBNA2, increases PD-L1 by down-
regulating miR-34a. Furthermore, in the presence of
EBNA2, pre-miR-34a and miR-34a promoter activity is
reduced and this suggests that EBNA2 affects miR-34a
transcription.
We found that miR-34a downregulation by EBNA2
likely involves recruitment of EBF1 at the miR-34a pro-
moter. Glaser et al. have recently shown that EBF1 interacts
with the N-terminal portion of EBNA2 in a B-cell specific
manner and this interaction promotes EBNA2 access to
chromatin, without involving RBPJk, a known EBNA2-
DNA anchor [19]. Our analysis of EBNA2 ChIP-Seq
datasets from GEO database (accession number:
GSM2039170) revealed that EBNA2 peaks at the miR-34a
promoter. Furthermore, the data showing the importance of
EBF1 in miR-34a regulation by EBNA2 is consistent with
previous suggestion that EBNA2 and EBF1 are colocalized
at EBNA2 peaks [19]. Recently it was also shown that Ten-
Eleven translocation 2 (TET2) is highly expressed in
latency III (EBNA2+) BLs and ABC DLBCLs [65].
Interestingly, EBNA2 colocalizes with both EBF1 and
TET2 [16, 66]. From our data, the role of EBF1 in negative
regulation of miR-34a is evident but the possibility that
EBNA2 could influence PD-L1 by affecting TET2 needs
further investigation. Overall, our data support the notion
that EBNA2/EBF1 involvement in miR-34a regulation can
Fig. 6 miR-34a relieves suppression of immunogenicity induced by
EBNA2 as measured in MLR and 3D biomimetic microfluidic
coculture devices. a T cells were activated in plates coated with anti-
CD3/anti-CD28 antibodies for 72 h. Irradiated targets U2932 MPA
vector and U2932 EBNA2 cl-1 were cocultivated with activated
T cells (effector). The effector-target ratio was 1:10. The target cells
were transfected with mimic control or miR-34a mimic 24 h prior to
cocultivation with the effector cells. The coculture was carried out for
48 h and the cells were stained for CD4/CD8 and IFN-γ and processed
for flow cytometry. Data are expressed as mean ± SD. The p values for
T-cell activation without stimulators are (*) p ≤ 0.05 for CD8 and CD4.
In MLR with U2932 stimulators, the statistical significance is (*) p=
0.028 for CD8 and (**) p= 0.0081 for CD4. Three different experi-
ments were performed with PBMCs isolated from three different
donors. b Three-dimensional biomimetic microfluidic coculture devi-
ces: Four million/ml U2932 EBNA2 cells tranduced with lentiviral
vector controls were introduced into the microfluidic devices. In
coculture experiments (right panel in b), devices were first seeded with
U2932 EBNA2 cells and were incubated for 24 h at 37 °C, followed by
activated T cells seeding. Immunostaining was performed after 48 h of
cocultivation. bi: Representative confocal images of U2932 EBNA2
cl-1 transduced with GFP-lentiviral vector control in the absence or
presence of activated T cells; bii Four million/ml U2932 EBNA2 cl 1,
tranduced with miR-34a lentivirus, were introduced in the collagen/
fibronectin devices either alone (left panel) or cocultivated with pre-
viously activated T cells (right panel). The cocultivation of target,
miR-34a transduced U2932 EBNA2 cells with activated T cells, was
carried out for 48 h before immunostaining. miR-34a containing
lentivirus-transduced U2932 EBNA2 cl-1 cells were stained with anti-
GFP antibody (green), activated CD8/CD4 T cells were stained with
anti-CD8 and anti-CD4 (magenta), apoptotic U2932 EBNA2 cl-1 cells
were visualized with anti-caspase-3 antibody (red), and nuclei were
counterstained with DAPI (blue). The overlap of miR-34a transduced
U2932 EBNA2 cells (GFP positive) and caspase-3 (red) indicates
tumor cell death (merged images, yellow). Scale bar= 100 μm, mag-
nification of the insets= scale bar 20 μm. c Arbitrary Caspase-3 units
were calculated for each experimental condition. Statistically sig-
nificant caspase-3 positive cells were observed only in miR-34a
tranduced EBNA2 expressors; Data expressed as mean ± SEM; (****)
p < 0.0001. N= 4 fields (3–4 devices for each experimental condition).
Shown is one representative experiment out of four performed. Sta-
tistical analysis was performed with Prism-7 software using unpaired T
test
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be therapeutically harnessed for DLBCL and particularly
for the drug resistant cases.
As mentioned earlier, EBNA2 is the main driver of
B-cell transformation induced by EBV. To this end, it is
noteworthy that c-MYC is directly upregulated by EBNA2
[12]. Additionally, EBNA2 is also a functional homolog of
activated Notch [15]. Both c-MYC and activated Notch are
known for their oncogenic properties. Most interestingly,
both these proteins are miR-34a targets [67, 68]. Based on
our data, we surmise that EBNA2 may not only be the
functional homolog of Notch but indeed it may help keep
Notch expression up through downregulation of miR-34a.
Casey et al. have recently shown that c-MYC can induce
PD-L1 expression [69]. Further studies will be required to
understand if EBNA2 by downregulating miR-34a
increases c-MYC, which in turn may upregulate PD-L1. At
present, it is not known if activated Notch genes like c-
MYC have any effect on PD-L1 expression. Based on our
data, this exciting possibility needs further investigation.
Increased tumorigenicity is often combined with poor
immunogenicity in cancer. Thus, the double-edged sword-
like function of EBNA2 to downregulate miR-34a through
EBF1 and consequently upregulate PD-L1 adds to the long
list of its oncogenic attributions. To argue against its rele-
vance, because EBNA2 expression is a rarity in lymphomas,
would be fallacious, particularly, if wider implications of our
findings are considered. EBV-induced immunoblastomas of
immunocompromised patients, such as in AIDS and trans-
plant, are EBNA2 expressors. A significant proportion of
cases within EBV-positive ABC DLBCLs are also EBNA2
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positive. The viral gene expression pattern in these tumors
resembles that of in vitro transformed LCLs and cellular
proliferation in both these cell types is indeed EBNA2 dri-
ven. Clearly, in patients with compromised T-cell immune
responses, therapeutic approaches like inactivation of
EBNA2 by Crispr-Cas9 gene editing and/or therapeutic
introduction of miR-34a mimics will have to be considered.
The 3D biomimetic microfluidic devices, described here
for the first time to test immunogenicity of lymphoma cells,
provide a quick and economically viable alternative to a
more expensive and cumbersome, humanized mouse-based
approaches for human tropic viruses like EBV. In addition,
these devices might also prove useful in testing the efficacy
of combinatorial immunotherapy agents, in lieu of huma-
nized mice.
In conclusion, the identification of EBNA2 as a lead
player in tampering with immunogenicity of EBV-infected
cells by altering PD-L1 and miR-34a opens up several new
RNA-aided immunotherapy avenues to explore. We pro-
pose a combinatorial delivery of antibodies and miR-34a to
silence PD-L1 both from within and without the cell to
maximize chances of a successful and potent therapy to
benefit immunocompetent patients with EBV-associated
cancers, but such an approach might have wider implica-
tions for other cancers as well.
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